CD274 and neoplasm: Likewise, the shift of a previously PD-L1 negative tumor to one that is PD-L1 positive, along with the temporal changes in the TME, may allow for improved effectiveness of PD-1 targeted checkpoint inhibitors as a co-therapy option.